1. Home
  2. CALC vs FLYX Comparison

CALC vs FLYX Comparison

Compare CALC & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • FLYX
  • Stock Information
  • Founded
  • CALC 2011
  • FLYX 2015
  • Country
  • CALC United States
  • FLYX United States
  • Employees
  • CALC N/A
  • FLYX N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • FLYX Blank Checks
  • Sector
  • CALC Health Care
  • FLYX Finance
  • Exchange
  • CALC Nasdaq
  • FLYX Nasdaq
  • Market Cap
  • CALC 48.1M
  • FLYX 39.4M
  • IPO Year
  • CALC N/A
  • FLYX N/A
  • Fundamental
  • Price
  • CALC $2.91
  • FLYX $3.49
  • Analyst Decision
  • CALC Strong Buy
  • FLYX
  • Analyst Count
  • CALC 2
  • FLYX 0
  • Target Price
  • CALC $14.50
  • FLYX N/A
  • AVG Volume (30 Days)
  • CALC 91.2K
  • FLYX 19.0K
  • Earning Date
  • CALC 08-12-2025
  • FLYX 08-13-2025
  • Dividend Yield
  • CALC N/A
  • FLYX N/A
  • EPS Growth
  • CALC N/A
  • FLYX N/A
  • EPS
  • CALC N/A
  • FLYX N/A
  • Revenue
  • CALC N/A
  • FLYX $347,746,000.00
  • Revenue This Year
  • CALC N/A
  • FLYX $28.47
  • Revenue Next Year
  • CALC N/A
  • FLYX $22.44
  • P/E Ratio
  • CALC N/A
  • FLYX N/A
  • Revenue Growth
  • CALC N/A
  • FLYX 17.09
  • 52 Week Low
  • CALC $1.42
  • FLYX $1.79
  • 52 Week High
  • CALC $5.97
  • FLYX $4.90
  • Technical
  • Relative Strength Index (RSI)
  • CALC 52.85
  • FLYX 74.06
  • Support Level
  • CALC $2.31
  • FLYX $2.16
  • Resistance Level
  • CALC $3.00
  • FLYX $2.60
  • Average True Range (ATR)
  • CALC 0.34
  • FLYX 0.33
  • MACD
  • CALC -0.12
  • FLYX 0.11
  • Stochastic Oscillator
  • CALC 40.00
  • FLYX 84.62

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About FLYX flyExclusive Inc.

flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.

Share on Social Networks: